Caribou Biosciences, Inc. (CRBU) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US1420381089
Caribou Biosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 11.16 m USD |
| Operating income | -148.34 m USD |
| EBIT | -148.68 m USD |
| Net income | -148.13 m USD |
| Diluted EPS – continuing operations | -1.59 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
More stocks
- HOOPS SCOUTING USA (HSCT)
- Emerita Resources Corp (EMO.V)
- Altamira Gold Corp (ALTA.V)
- SebitChem Co. Ltd. (107600.KQ)
- Sow Good Inc. (SOWG)
- CRYO CELL INTERNATIONAL INC (CCEL)
- biote Corp. (BTMD)
- Mount Logan Capital Inc. (MLCI)
- PBG S.A (PTBL3.SA)
- UNITED GUARDIAN INC (UG)
- Model Solution Co., Ltd. (417970.KQ)
- ENTREPRENEUR UNIVERSE BRIGHT GROUP (EUBG)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.